Does anybody know of a site or any information that would show the procedure for creating insulin from pigs?
I want to know what you would have to do in order to extract and purify insulin from pigs so you could use it to treat diabetes mellitus. I am a diabetic myself, and am quite weary of what is really going on behind the scenes and what the evil pharmeceutical companies are putting into Humalog, and other unnaturally fast acting insulin analogs. My suspicions are proved even further now, because I just read the pork insulin regular is no longer being produced in Canada. So it looks like I'll have to learn how to produce it myself.
Diabetes - 2 Answers
Random Answers, Critics, Comments, Opinions :
1 :
LOL Are you really that uninformed about diabetes or are you just trying to stir up yet another conspiracy theory to amuse yourself? Animal based insulins are not the primary sources of human insulin anymore, and quite likely, you've never used either the beef or pork variety (unless you've been type 1 more than 30 years). Insulin today is primarily made through recombinant DNA processes where human insulin is excreted by special bacteria. While there has been research in adding human DNA to pigs and cows to produce human enzymes through their products such as milk, it is still outrageously expensive to do it that way considering the sheer number of diabetics. Canada, like many other countries and pharmacuetical laboratories, has stopped producing animal based insulins because there is not enough need for them. It is not a conspiracy. BTW you'd have to own a lot of pigs and all the equipment to make your own insulin that way. You'd need to be able to kill at the very minimum one pig a day, dessicate the pancrease, and extract and purify the insulin. Not an easy process, either, and if you do it wrong, you're dead. You don't have the knoweldge or expertise to make your own with recombinant DNA either.
2 :
I think a better choice for you: In 1996 a 41 year old diabetic was injected with LCT's prototype diabetes product containing pig islet cells to help regulate his blood glucose levels and control of diabetes. The transplanted cells helped reduce the patient's insulin requirement by 34% for over a year, which provided better control and overall well-being. By 2005 the patient's glycated hemoglobin levels remained lower than the pre-transplant levels pointing to improved long-term control of blood glucose levels. Ten years later the patient suggested that he was still obtaining benefit from the transplant. LCT scientists assumed that the cells would not be alive or functioning after that period of time, but the patient convinced LCT scientists to organise for a laparoscopy to check. This resulted in finding both living and functioning pig islet cells in his abdomen. "This has never been achieved before. It is a profound step forward for safe, effective and long-term diabetes control and shows the ability for pig cells to survive inside a human for an extended period of time and without immune suppression," commented Prof Bob Elliott, LCT Medical Director. Dr Christina Buchanan, a biochemist from the University of Auckland and an expert in insulin, conducted the analysis to ensure that the insulin detected in the patient's blood samples were unequivocally pig and not human insulin - the final proof of efficacy. Dr John Court, a diabetologist and scientific advisor to LCT said: "This is only one patient's experience but it does show that pig cells can survive at least ten years in a micro-capsule coating and continue to release insulin into the patient's bloodstream." LCT has significantly advanced the encapsulation process since the 1996 clinical trial and there is an even greater understanding and control over the longevity and robustness of the encapsulation process, as well as the porcine islet cells. The product is produced under a GMP manufacturing license. LCT will be trialing the DiabeCell® pig islet cell transplant in patients in a phase I/IIa clinical trial, expected to begin in Quarter 2, 2007. In addition, LCT is awaiting approval to conduct an additional trial in New Zealand this year with a different treatment protocol. Subsequent trials in the US or Europe are intended following initial results from these studies. The trial will involve the simple injection of encapsulated neo-natal pig islet cells into the peritoneal (abdominal) cavity of the diabetic patients. The procedure is quite simple and carried out under local anaesthetic. Patients will then be monitored by LCT's well established protocols, which are in accordance with international xenotransplantation guidelines. "This is strong evidence that LCT's DiabeCell® product holds significant potential to address the key issues of finding renewable donor cells and not using immunosuppression, as outlined in the National Institutes of Health (USA) and Juvenile Diabetes Research Foundation (JDRF) strategic plans," said Dr Paul Tan, LCT's CEO. "LCT's clinical trial program intends to test three different treatment regimens, in order to find the most appropriate, long-lasting and effective transplant possible," Dr Tan said. DiabeCell® is a porcine pancreatic cell product for the treatment of insulin-dependent diabetes. The neo-natal pig cells produce insulin and help regulate blood glucose levels appropriate to the amount of glucose detected in the blood stream of the diabetic recipient. Extensive pre-clinical testing of DiabeCell® in animal models has shown no adverse effects with any dose or repeated transplants, extended survival of the islets a significant reduction in insulin requirements, and prolonged insulin independence in some individual animals.- Good luck
Read more discussions :
